Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Update: CPAP May Not Improve Glycemic Control in People with Diabetes

March 11, 2016 By American Thoracic Society (ATS)

People with type 2 diabetes and obstructive sleep apnea (OSA) may not experience improved glycemic control by using continuous positive airway pressure, or CPAP, as some studies have suggested, according to the results of a randomized, controlled trial published online ahead of print in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.

“Many studies have indicated that OSA may contribute towards the development and progression of type 2 diabetes,” said lead study author Jonathan Shaw, MD, associate professor and head of population health at Melbourne’s Baker IDI Heart and Diabetes Institute “However, proving that link, and determining if treating OSA could have benefits for glucose control, requires intervention studies. Some uncontrolled studies had reported improved glucose control after starting CPAP, but some small controlled trials did not support this.”

In “The Effect of Treatment of Obstructive Sleep Apnea on Glycemic Control in Type 2 Diabetes,” researchers in Australia and the U.S. randomly assigned 298 patients with “relatively well-controlled” type 2 diabetes and newly diagnosed OSA to either treat their sleep apnea with CPAP or receive usual care.

In addition to measuring the change in glycemic control, researchers studied changes in blood pressure, daytime sleepiness and quality of life over six months. Researchers found:

  • No difference between those receiving CPAP and the control group in change in glycated hemoglobin (HbA1c) at three and six months. 
  • Greater fall in diastolic blood pressure over six months in the CPAP group compared to controls—a finding that was statistically significant only among those who used CPAP for at least four hours a night.
  • Daytime sleepiness improved significantly among those using CPAP as measured by the Epworth Sleepiness Index.
  • Quality of life between the two groups was not statistically significant overall as measured by the RAND 36-Item Short Form Health Survey. Among those using CPAP for at least four hours a night, there was a significant difference with controls on vitality and mental health subscores.

Authors offered several possible explanations for why participants using CPAP did not experience better glycemic control. OSA may play a bigger role in the development of diabetes than in the control of established diabetes. The bar for adherence to CPAP—set at four hours a night—may have been set too low. And, lastly, CPAP may only benefit those with severe OSA and/or poor glycemic control. Participants with those characteristics were not well represented in the study, the authors noted.

“OSA is common in people with type 2 diabetes, and although we did not find a glycemic benefit for its treatment, clinicians should have a high index of suspicion for its presence when patients experience daytime sleepiness, snoring and resistant hypertension,” Dr. Shaw said. “Identification and treatment of OSA in these patients may lead to clinically meaningful benefits.”

Another study published recently online in the American Journal of Respiratory and Critical Care Medicine looked at CPAP and glucose control in patients whose diabetes was not well controlled. That study, also a six-month randomized controlled trial, found that CPAP significantly improved glycemic control at six months, but not three.

Atul Malhotra, MD, president of the American Thoracic Society and a sleep expert not involved in either study, said there were a number of possible explanations for the different results, including differences in glucose control at baseline and the relatively small size of the studies.

“Differences in race and ethnicity and changes in diet, exercise and metabolism that may occur with CPAP, may have also contributed to the different findings,” said Dr. Malhotra, chief of pulmonary and critical care medicine and director of sleep medicine at the University of California, San Diego, who said there was a need for more research on the subject.

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
A portrait of Dexcom VP of Global Clinical Initiatives Tomas Walker
Dexcom focuses on early diabetes diagnosis as COVID links emerge
A portrait of Proximie CEO Nadine Hachach-Haram
They said it at DeviceTalks Boston
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech